However, in these studies, the levels of CSF GFAP in Alzheimer’s disease patients, when compared with those of other neurodegenerative diseases, were not significantly different and, therefore, of limited diagnostic value [232,233,234,235]. This evidence concerns the gene GFAP and neurodegenerative disease.